BIOLASE, Inc.
BIOLQ
$0.0078
$0.00034.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 46.03M | 46.10M | 48.83M | 49.16M | 49.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.03M | 46.10M | 48.83M | 49.16M | 49.73M |
| Cost of Revenue | 30.18M | 30.88M | 32.10M | 32.44M | 32.93M |
| Gross Profit | 15.85M | 15.22M | 16.72M | 16.73M | 16.80M |
| SG&A Expenses | 24.45M | 26.37M | 28.15M | 28.66M | 31.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.54M | 62.62M | 66.00M | 67.10M | 71.01M |
| Operating Income | -13.52M | -16.52M | -17.17M | -17.94M | -21.29M |
| Income Before Tax | -16.00M | -19.16M | -21.22M | -20.60M | -25.03M |
| Income Tax Expenses | 36.00K | 39.00K | 50.00K | 32.00K | 133.00K |
| Earnings from Continuing Operations | -16.04 | -19.20 | -21.27 | -20.63 | -25.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.04M | -19.20M | -21.27M | -20.63M | -25.17M |
| EBIT | -13.52M | -16.52M | -17.17M | -17.94M | -21.29M |
| EBITDA | -10.90M | -13.98M | -13.86M | -15.14M | -19.03M |
| EPS Basic | -7.85 | -18.16 | -44.21 | -66.06 | -186.47 |
| Normalized Basic EPS | -1.40 | -3.80 | -9.30 | -22.96 | -101.01 |
| EPS Diluted | -7.85 | -18.16 | -44.21 | -66.06 | -186.47 |
| Normalized Diluted EPS | -1.40 | -3.80 | -9.30 | -22.96 | -101.01 |
| Average Basic Shares Outstanding | 90.35M | 55.44M | 22.60M | 5.02M | 2.06M |
| Average Diluted Shares Outstanding | 90.35M | 55.44M | 22.60M | 5.02M | 2.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
